Sequential polychemotherapy for advanced prostatic carcinoma. A preliminary cooperative study on 30 patients

Area of Science:

• Oncology
• Medical Oncology
• Cancer Treatment Research

Background:

• Advanced prostate carcinoma presents significant treatment challenges.
• Effective palliative care, including pain management, is crucial for patient quality of life.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a sequential polychemotherapy regimen for advanced prostate cancer.
• To assess the impact of adriamycin addition on treatment outcomes.

Main Methods:

• A cohort of 30 patients with advanced prostate carcinoma received sequential polychemotherapy.
• The regimen included vincristine (or VM 26), cyclophosphamide, and 5-fluorouracil.
• A subset of 13 patients received an additional dose of adriamycin on day one.

Main Results:

• The sequential polychemotherapy regimen was well tolerated by patients.
• Significant relief of bone pain was observed in patients receiving the treatment.
• The addition of adriamycin did not significantly change the observed treatment results.

Conclusions:

• Sequential polychemotherapy with vincristine, cyclophosphamide, and 5-fluorouracil is a viable and tolerable treatment option for advanced prostate cancer.
• This regimen offers effective palliation of bone pain, improving patient quality of life.